Physician profile
Qing Yeh
NPI 1104834324
$14,590.71
in general payments reported to CMS, 2019-2025
30 companies · $2,245 in 2025
The $2,245 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,474 · 2020: $1,095 · 2021: $2,314 · 2022: $2,126 · 2023: $2,296 · 2024: $2,041 · 2025: $2,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,581.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,721.61 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $1,869.14 | 2019-2025 | Ubrelvy, Qulipta, Linzess |
| Gilead Sciences, INC. | $1,793.89 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,573.63 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,417.55 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,114.50 | 2019-2025 | Spiriva Respimat, Jardiance |
| Phathom Pharmaceuticals, INC. | $679.70 | 2023-2025 | Voquezna |
| Esperion Therapeutics, INC. | $480.04 | 2021-2025 | Nexletol |
| Novo Nordisk INC | $370.38 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $302.90 | 2022-2024 | |
| Aimmune Therapeutics, INC. | $247.62 | 2024-2025 | Zenpep |
| Amarin Pharma, INC. | $240.24 | 2019-2023 | |
| Nestle Healthcare Nutrition INC. | $226.18 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $184.99 | 2022 | |
| Ironwood Pharmaceuticals, INC | $182.64 | 2020-2025 | Linzess |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $158.19 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $147.93 | 2019-2021 | |
| Horizon Therapeutics Plc | $138.83 | 2022-2023 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $119.23 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $113.48 | 2019 | |
| Lilly USA, LLC | $108.67 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $93.28 | 2022-2024 | |
| Allergan, INC. | $77.20 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.89 | 2019-2023 | Trulance, Xifaxan |
| Ibsa Pharma INC. | $39.73 | 2021 | |
| Corium, LLC | $37.05 | 2022-2023 | Adlarity |
| Seqirus USA INC | $34.24 | 2024-2025 | Flucelvax, Fluad |
| Corcept Therapeutics | $21.56 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $20.50 | 2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $15.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qing Yeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.